Tumor Resistance to Molecularly Targeted Agents

Autor:	Robert A. Lustig, Lucien Ooi, James Chen, Peter S. Edelstein, Philip J. Johnson
Rok vydání:	2011
Předmět:	Side effect Oncogene Renal cell carcinoma Cancer research medicine Cancer Secondary tumors Biology Pharmacology medicine.disease Tyrosine kinase Tumor resistance Gene pathway
Zdroj:	Journal of Cancer Therapy. :258-265
ISSN:	2151-1942 2151-1934
DOI:	10.4236/jct.2011.22033
Popis:	Despite the development of new targeted cancer therapies, primary and secondary tumors continue to be a leading cause of suffering and mortality worldwide. The complexity and heterogeneity of malignancies ultimately result in tumor resistance to therapies, such as EGFR inhibitiors, anti-angiogenesis agents, and tyrosine kinase inhibitors. An example of targeted therapies for renal cell carcinoma is presented, including the SAE profile and efficacy of 6 targeted agents. Although survival is improved, resistance and an increased side effect profile diminish the benefits of these agents. New agents are needed which are pathway independent and which can overcome tumor resistance without adding to the side effect profile of current therapies.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::bbac603b44b6856fd63d5ef3f24fc01f https://doi.org/10.4236/jct.2011.22033 Zobrazit plný text záznamu